Researchers: Masayoshi Suda, Karl H Paul, Tohru Minamino, Jordan D Miller, Amir Lerman, Georgina M Ellison-Hughes, Tamar Tchkonia, James L Kirkland
Senescent cell accumulation has been observed in age-associated diseases including cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence-associated secretory phenotype (SASP) factors that may cause or worsen many cardiovascular diseases. Therapies targeting senescent cells, especially senolytic drugs that selectively induce senescent cell removal, have been shown to delay, prevent, alleviate, or treat multiple age-associated diseases in preclinical models. Some senolytic clinical trials have already been completed or are underway for a number of diseases and geriatric syndromes. Understanding how cellular senescence affects the various cell types in the cardiovascular system, such as endothelial cells, vascular smooth muscle cells, fibroblasts, immune cells, progenitor cells, and cardiomyocytes, is important to facilitate translation of senotherapeutics into clinical interventions. This review highlights: (1) the characteristics of senescent cells and their involvement in cardiovascular diseases, focusing on the aforementioned cardiovascular cell types, (2) evidence about senolytic drugs and other senotherapeutics, and (3) the future path and clinical potential of senotherapeutics for cardiovascular diseases.
References
- The intersection between aging and cardiovascular disease.
- Targeting cellular senescence in metabolic disease.
- Loss of epigenetic information as a cause of mammalian aging.
- A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues.
- Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans.
- Mechanisms and consequences of endothelial cell senescence.
- Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics.
- Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases.
- Cellular senescence and senolytics: the path to the clinic.
- The hallmarks of aging.
- Cellular senescence in skin-related research: Targeted signaling pathways and naturally occurring therapeutic agents.
- Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy.
Topic: Senolytics